NCT06932094View on ClinicalTrials.gov

Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

256

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

February 29, 2028

Conditions

Advanced Solid Tumors

Interventions

DRUG

QLS5132

antibody drug conjugate (ADC).

Trial Locations (1)

Unknown

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY